Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
492 Leser
Artikel bewerten:
(1)

Clever Leaves Partners With FoliuMed to Import Colombian Cannabis EU-GMP Bulk Extracts Into Germany

A supply agreement between cannabis operators Clever Leaves and FoliuMed allows for the exportation of pharmaceutical grade cannabis bulk extracts from Colombia to Germany.

BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, has signed a one-year international sales agreement with German- Colombian operator FoliuMed Holdings ("FoliuMed") and its German manufacturing partner, Fidelio Healthcare ("Fidelio"). With access to three of Clever Leaves' pharmaceutical grade bulk cannabis extracts, Fidelio will be ramping up production using Clever Leaves' full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate.

With high production standards recognized domestically and abroad, including both Good Manufacturing Practices (GMP) certification from Colombia and European Union Good Manufacturing Practices (EU GMP) certification from Europe, Clever Leaves' Colombian pharmaceutical-grade cannabis will be utilized by Fidelio's manufacturing and distribution teams to create affordable, orally administered gel capsules for consumption on a prescription basis by customers and patients in Australia, Europe and Latin America. Soft gel capsules are preferred by patients and doctors as they can be dosed more precisely than the market standard cannabis tinctures.

"Leveraging our Colombian operation to build and maintain relationships throughout the cannabinoid and pharmaceutical industry is incredibly important to us," said Andrés Fajardo, President and incoming CEO of Clever Leaves in regard to the emerging partnership with FoliuMed. "We're grateful for the opportunity to expand our international presence by partnering with FoliuMed and Fidelio, bringing Clever Leaves standard of production to a global scale."

"FoliuMed and our manufacturing partner Fidelio are one of the five producers worldwide who manufacture cannabis soft gels for prescription medicines under EU-GMP", said FoliuMed CEO Oliver Zugel. "We carefully chose Clever Leaves as our preferred raw material supplier for this highly strategic product range. As we are seeing increased customer interest for soft gels, we will expand our range of formulations and are looking forward to work with Clever Leaves in this endeavor."

Clever Leaves raw materials are shipped to FoliuMed's German operation near Frankfurt where they are processed into soft gels at Fidelio's EU-GMP contract manufacturing site and delivered to a leading Australian customer in the first quarter of 2022. With Clever Leaves recently making headlines as the first to export raw THC flower from Portugal to the U.S., and with this latest international agreement, Clever Leaves continues to demonstrate its ability to expand its distribution globally, meeting the highest standards required both by Germany, Australia and the European Union.

About Clever Leaves Holdings Inc.

Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids. Its operations in Colombia and Portugal produce cannabinoid active pharmaceutical ingredientsand follow Clever Leaves on Twitter and LinkedIn.

About FoliuMed

FoliuMed is an international cannabis company with EU-GMP manufacturing operations (highest European production standard of ‚Good Manufacturing Practise') in Germany. Sourcing cannabinoid ingredients from its organic cultivation in Colombia, it provides a broad range of affordable and efficacious pharma-grade cannabis medicines "made in Germany". The company is one of the few EU-GMP cannabis soft gel manufacturers in the world supplying customers in eight countries on three continents. FoliuMed also works as a contract manufacturer and white label producer for some of the leading cannabis players in Germany, Australia, the US and South America.

Clever Leaves Press Contacts:
Rich DiGregorio
KCSA Strategic Communications
+1-856-889-7351
cleverleaves@kcsa.com

Diana Sigüenza
Strategic Communications Director
+57-310-236-8830
diana.siguenza@cleverleaves.com

Clever Leaves Commercial Inquiries:
Andrew Miller
Vice President Sales - EMEA, North America, and Asia-Pacific
+1-416-817-1336
andrew.miller@cleverleaves.com

Clever Leaves Investor Inquiries:
Cody Slach and Jackie Keshner
Gateway Investor Relations
+1-949-574-3860
CLVR@gatewayir.com

FoliuMed Contact:
Oliver Zugel
CEO
ozugel@foliumed.com

Fidelio Contact:
Dr. Armin Prasch
Research and Strategic Development
Armin.prasch@fidelio-healthcare.com


© 2022 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.